A Phase 2 interventional study of SHR-1905 and placebo in Asthma, sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Asthma by Jiangsu HengRui Medicine Co., Ltd. — 5 open to participants now, 6 under way, 2 of them phase 3. Asthma · Jiangsu HengRui Medicine Co., Ltd..
Among the 15 studies in Asthma by Jiangsu HengRui Medicine Co., Ltd., this one is the 3rd largest by enrollment, is the only one that started in 2023, is one of 6 in phase 2, and was the 8th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →5 of the 15 studies in Asthma by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:
Guangdong Hengrui Pharmaceutical Co., Ltd · Sites in China
Ages 18+
Jiangsu HengRui Medicine Co., Ltd. · Sites in China
Ages 18–75
Guangdong Hengrui Pharmaceutical Co., Ltd · Sites in China
Ages 18+
Guangdong Hengrui Pharmaceutical Co., Ltd · Sites in China
Ages 18–55 · Healthy volunteers
Guangdong Hengrui Pharmaceutical Co., Ltd · Sites in China
Ages 18–75
By country, each count listing its studies:
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2020; this study’s year is marked. 1 started in 2023.
This study's enrollment of 260 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 84 across the 15 interventional studies. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Shanghai Hengrui Pharmaceutical Co., Ltd., one of the names counted as Jiangsu HengRui Medicine Co., Ltd.. Under that name alone:
Shanghai Hengrui Pharmaceutical Co., Ltd. is the lead sponsor of 61 studies on the registry; 30 are open to participants now.
3 of the studies in Asthma by Jiangsu HengRui Medicine Co., Ltd. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06653322Phase 3Guangdong Hengrui Pharmaceutical Co., LtdA Multi-centered,Randomized,Double-blind,Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR-1703 in Eosinophilic Asthma | 2027-09 |
| NCT07701239Guangdong Hengrui Pharmaceutical Co., LtdA Study Comparing a Pre-filled Safety Syringe and an Autoinjector for SHR-1703 Injection in Healthy Participants | 2027-04 |
| NCT06775340Jiangsu HengRui Medicine Co., Ltd.Study of RSS0343 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis | 2027-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 15 studies in Asthma by Jiangsu HengRui Medicine Co., Ltd., from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a phase 2 study of SHR-1905 in subjects with severe uncontrolled asthma. The purpose of the study is to evaluate efficacy and safety of SHR-1905 in subjects with severe uncontrolled asthma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
dose 1
Drug: SHR-1905
dose 2
Drug: SHR-1905
dose 3
Drug: SHR-1905
Drug: placebo
subcutaneous
subcutaneous ,placebo
Efficacy:Annual asthma exacerbation rate (AAER)
Time frame: From randomisation to 48 weeks
Changes of fractional exhaled nitric oxide (FeNO) compared with baseline
Time frame: Baseline to72 weeks
Changes from baseline in Asthma Control questionnaire (ACQ-6) scores
Time frame: Baseline to 72 weeks
Changes from baseline in Asthmatic Quality of Life Questionnaire (AQLQ) scores
Time frame: Baseline to 72 weeks
AAER associated with hospitalization at 48 weeks
Time frame: From randomisation to 48 weeks
Changes from baseline in Asthma Symptom Diary scores
Time frame: Baseline to 72 weeks
The proportion of subjects with acute exacerbations of asthma
Time frame: Baseline to 72 weeks
Changes from baseline in weekly reliever use
Time frame: Baseline to 72 weeks
Changes from baseline in weekly mean morning and evening peak expiratory flow (PEF)
Time frame: Baseline to 72 weeks
Changes from baseline in weekly mean number of night time awakenings
Time frame: Baseline to 72 weeks
Time to the first acute asthma exacerbation
Time frame: Baseline to 72 weeks
The proportion of subjects with composite endpoint for asthma (CompEx)
Time frame: Baseline to72 weeks
Pharmacokinetics (PK): Serum concentration of SHR-1905
Time frame: 72 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jan 2023 to primary completion in Dec 2025, 34 months.
Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 34 months is above that.
Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Dec 2026 → Dec 2025 and completion Dec 2026 → May 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: SHR-1905
Shanghai Hengrui Pharmaceutical Co., Ltd. →